..
If there was any doubt that John Campbell is now just a grifter cashing in on his antivax audience, this thread dispels it. https://t.co/qLlzDbYOZj
— Dr Susan Oliver (PhD) (@DrSusanOliver1) May 22, 2023
..
Is this video a joke, John? You've turned from a trusted science communicator to a tabloid screaming fear-mongering, bolded headlines in the checkout line.
— Jonathan Laxton MD, FRCPC (@dr_jon_l) May 22, 2023
..
Itβs hard to conclude this is ignorance. The guy KNOWS what a Phase I trial is and what an appropriate size is.
— Alastair McAlpine, MD (@AlastairMcA30) May 22, 2023
So this is just shameless grift, pandering to his antivaxx audience.
Appalling.
His entire outrage is that 50 people is too small for a Phase I trial.
— Alastair McAlpine, MD (@AlastairMcA30) May 22, 2023
But itβs perfectly sized for a Phase I trial (typically 20-100 folks).
So the entire video is meaningless.
Phase I studies are the first human trials (they are needed to test the dose and ensure safety for later phases). Only in later phases (II and III) are more people recruited. It is sad to see this absurd transformation of Campbell, ignoring the most basic concepts.
— Pills of Science (@pills_ofscience) May 22, 2023
..
Checking in with John Campbell. God he is shameless.
— bad_stats ππ΅π¨οΈπ£ (@thebadstats) May 22, 2023
Feigned outrage over a Phase 1 clinical trial with 50 participants for mRNA flu vaccine.
Yah… that's how big Phase 1 clinical trials are. He very intentionally never gives the audience context for what a phase 1 trial is pic.twitter.com/GyrjHt7LZa
december 13 2020 pic.twitter.com/ePt5PsEzXK
— bad_stats ππ΅π¨οΈπ£ (@thebadstats) May 22, 2023
august 9th 2020
— bad_stats ππ΅π¨οΈπ£ (@thebadstats) May 22, 2023
"standard procedure for any vaccine… phase one will be on a small number of healthy volunteers" pic.twitter.com/8OXlQoHY5s
June 26 2020 pic.twitter.com/CJGFQacz5V
— bad_stats ππ΅π¨οΈπ£ (@thebadstats) May 22, 2023
I added this to his video. Will he delete it? pic.twitter.com/yav4guvqGd
— George Carey (@GeoFreC) May 22, 2023
..